Novamind Inc. (CSE:NM) CEO Yaron Conforti tells Proactive the Toronto-based group is looking to scale its mental health clinics and its clinical research sites as policy around psychedelic drugs shifts in the US and around the world. Conforti says part of the group's plan when it chose to go public, was to expand its reach into the US. The group currently has mental health clinics in various locations in Utah, and offers its clients access to ketamine therapies.
Novamind looks to scale mental health clinics and clinical sites with shift in psychedelics policies
Quick facts: Novamind Inc
Price: 0.63 CAD
Market Cap: $26.16 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE